Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

GLP-Compliant IND-Enabling Toxicology for AAV8 Liver-Directed Gene Therapies in NHP Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

GLP-Compliant IND-Enabling Toxicology for AAV8 Liver-Directed Gene Therapies in NHP Models

GxP-Compliant IND-Enabling Toxicology for AAV8 Liver-Directed Gene Therapies

CELL & GENE | RNA | BIOLOGICS

    What are the primary toxicology endpoints for an AAV8 liver-directed gene therapy in NHP models?

    A: Key endpoints include the assessment of potential liver injury via clinical chemistry (e.g., ALT, AST, bilirubin), comprehensive histology of the liver and non-target tissues, vector DNA biodistribution analysis via qPCR or ddPCR, transgene expression kinetics, and a full immunogenicity profile, including anti-capsid and anti-transgene antibody responses.

    How does pre-existing AAV immunity in NHPs affect study design?

    A: Pre-existing neutralizing antibodies (NAbs) against AAV capsids are a key biological variable. We conduct rigorous NAb screening prior to study initiation to select seronegative animals or to stratify cohorts appropriately. This ensures that the observed safety and efficacy data are a direct result of the therapeutic candidate, not confounded by pre-existing immunity.

    Why is AAV8 a preferred serotype for liver-directed therapies?

    A: AAV8 demonstrates a strong, natural tropism for hepatocytes, leading to efficient and stable transgene expression in the liver. Its performance and safety profile have been well-characterized in multiple preclinical models, making it a robust and frequently selected candidate for liver-directed gene therapy programs.

An IND-enabling toxicology study in non-human primate (NHP) models is a definitive step in de-risking AAV8 liver-directed gene therapies. A successful program requires a study design that accounts for the specific biology of the vector, including its hepatotropism and potential immunogenicity. Key considerations include rigorous screening for pre-existing neutralizing antibodies, defining dose-response relationships, and executing a comprehensive panel of safety endpoints from clinical observations to molecular biodistribution and histology. This approach generates the robust safety data package required for regulatory submission.

Characterizing AAV8 Hepatotropism and Safety Profiles

Selecting an AAV serotype with high liver tropism is fundamental for developing hepatic gene therapies. Foundational research systematically evaluating various AAV vectors identified AAV8 as a superior candidate for liver-directed applications due to its capacity for high and stable transgene expression without associated toxicity (PMID: 19861950). This inherent biological targeting is the basis for its utility.

An effective IND-enabling program builds on this knowledge by designing toxicology studies that confirm and quantify this behavior in a relevant large animal model. The study must verify that the observed biological activity is concentrated in the target organ and that transgene expression is durable, providing an early indication of potential therapeutic efficacy.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Navigating Pre-existing Immunity in Translational Models

A significant translational challenge for AAV vectors is the presence of pre-existing immunity in the NHP population, which mirrors the human population. The impact of neutralizing antibodies on vector performance is a primary variable that must be controlled. Studies have demonstrated that pre-existing immunity can alter vector biodistribution and subsequent gene expression, directly affecting study outcomes (PMID: 19888196).

A standard component of our study design is a comprehensive NAb screening program. This allows for the selection of seronegative animals, ensuring that the safety and biodistribution data collected are an unconfounded reflection of the vector’s intrinsic properties.

IND-Enabling Toxicology Study Design for AAV8

A robust toxicology study is designed to meet regulatory expectations for an IND submission, typically within an 18-24 month timeline. Our approach integrates multiple assessments to build a comprehensive safety profile.

  • Dose-Range Finding (DRF): Preliminary non-GxP studies to identify a safe and biologically active dose range.

  • Pivotal GxP Study: The definitive study conducted in our >100,000 sq ft facility to GxP standards, evaluating the No Observed Adverse Effect Level (NOAEL).

  • Biodistribution: Quantitative assessment of vector DNA distribution in all relevant tissues, with a focus on the liver, gonads, and non-target tissue biodistribution.

  • Immunogenicity: Measurement of anti-AAV8 capsid binding and neutralizing antibodies, as well as T-cell responses and anti-transgene protein antibody formation.

  • Histology: Full histological analysis performed by board-certified pathologists to identify any microscopic tissue changes.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Animal Welfare and the 3Rs in NHP Studies

All studies are conducted in full compliance with USDA regulations and in facilities accredited by AAALAC International. We strictly adhere to the principles of the 3Rs (Replacement, Reduction, and Refinement) to ensure the highest standards of ethical and humane animal care.

Franklin Biolabs has supported a 100% IND success rate for client programs since 2019, a legacy of scientific excellence carried forward by the team that launched the Franklin Biolabs brand in 2024.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities